Amalgamation/Merger

Alkem Laboratories' subsidiary, Alkem Medtech Private (AMPL), is merging with its own wholly-owned subsidiary, Alkem Medtech Ortho Private (AMOPL). This move aims to simplify the group structure, optimize operations, reduce costs, enhance efficiency, and expand the combined entity's product portfolio.

Financials (as of March 2025): AMOPL had a paid-up capital of ₹3.50 Cr and negative net worth of (₹12.12 Cr), while AMPL had ₹380.38 Cr paid-up capital and ₹448.11 Cr net worth.

There will be no share swap or dilution for Alkem Labs shareholders, as it's a merger of wholly-owned step-down subsidiaries.

The scheme requires NCLT approval.